M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Biosimilar Filgrastim Initiation in Patients Enrolled in the Monitor G-CSF Observational Study Relative to EORTC Guidelines
Matti Aapro,Pere Gascón,Heinz Ludwig,Carsten Bokemeyer,Mario Boccadoro,Matthew Turner,M. Muenzberg,Kris Denhaerynck,Ivo Abraham,Karen MacDonald +9 more
TL;DR: Variability exists in biosimilar filgrastim initiation by tumour type (day of initiation), CT toxicity and patient-related risk, and about a quarter of patients with FN risk >20% or 10-20% in combination with other risk factors did not receive primary prophylaxis as recommended.
Journal ArticleDOI
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
Gian Maria Zaccaria,Gian Maria Zaccaria,Simone Ferrero,Andrea Evangelista,Samanta Rosati,Cristina Castagneri,Marco Ghislieri,Barbero Daniela,Elisa Genuardi,Mariella Lo Schirico,Alberto Zamò,Umberto Vitolo,Riccardo Bomben,Valter Gattei,Sara Galimberti,Antonello Di Paolo,Davide Rossi,Gianluca Gaidano,Alice Di Rocco,Sergio Cortelazzo,Mario Boccadoro,Gabriella Balestra,Marco Ladetto +22 more
TL;DR: The DELPHI DW as discussed by the authors tool is a powerful tool that identifies novel associations between multiple issues, every confounding issue, and every interaction between issues, which can be used for data quality and association analysis.
Journal ArticleDOI
The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.
Irene Ricca,Alberto Rocci,Marco Ruella,Manuela Zanni,Daniele Caracciolo,Marco Ladetto,Mario Boccadoro,Dario Ferrero,Corrado Tarella +8 more
TL;DR: A marked telomere loss seems to be a predictive marker of the development of sMDS/AML following ASCT; TL analysis can now be considered among follow-up assays, in order to early identify patients at high-risk of s MDS/ AML occurrence following autograft.
Journal ArticleDOI
Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients
Manuela Gambella,Paola Omedè,Daniela Drandi,Francesca Patriarca,Federica Cavallo,Maria Teresa Petrucci,Caravita Tommaso,Giulia Benevolo,Norbert Pescosta,Stefania Oliva,Massimo Offidani,Vittorio Montefusco,Anna Marina Liberati,Antonietta Falcone,Stelvio Ballanti,Tonino Spadano,Tommasina Guglielmelli,Pellegrino Musto,Renato Zambello,Francesco Di Raimondo,Marco Ladetto,Mario Boccadoro,Antonio Palumbo +22 more
TL;DR: The possible role of MRD monitoring to better assess the response to therapy also during maintenance and as marker of early relapse is suggested.
Salvage treatment with pomalidomide-cyclophosphamide prednisone produces similar outcomes as compared to prior therapies in patients with relapsed/refractory multiple myeloma
Alessandra Larocca,Vittorio Montefusco,Stefania Oliva,Mauro Spriano,A. Santagostino,Mariella Genuardi,D. Rota Scalabrini,Tommasina Guglielmelli,Nicola Giuliani,A. Moscetti,Roberto Mina,Magda Marcatti,Monica Galli,M. Gilestro,Claudia Crippa,Ileana Baldi,Davide Rossi,Mario Boccadoro,Paolo Corradini,Antonio Palumbo +19 more